Latest Conference Articles

Leading eating disorder expert Evelyn Attia, MD, sat down with MD Mag at the American Psychiatric Association meeting to talk about the correlation between obesity and eating disorders.

A leading expert on eating disorders sits down with MD Magazine at the Annual Meeting of the American Psychiatric Association meeting.

"We shouldn't reject these hypotheses, we should seek more data on them.

He and a Danish team believe they've found the cause of multiple sclerosis.

Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.

Brenda Banwell, MD, FAAP, FRCPC, chief of Childrens Hospital of Philadelphia's Division of Neurology, speaks on new discoveries of pediatric MS at the annual 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans.

The multi-dosage longterm studies of Cladribine Tablets were shared at CMSC.

The study was a continuation of a 2-year alemtuzumab study versus interferon.

The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.

Simvastatin may reduce inflammation, fibrosis, bronchial constriction, mucus

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Telepsychiatry shown to be viable alternative in rural areas with limited access.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Physicians debated the case of a 65-year-old woman with SPMS.

Physicians debated whether they would prescribe the new MS drug to a patient.

Doctors need to conduct clinical trials and define the disease.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Neomi Shah, MD, MPH, studied patients with sleep apnea to uncover its effect on arterial inflammation.

Valerie Page, MB, BCh, FRCA, recounts a study of simvastatin on delirium patients.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

An overview of the newest treatment options for the disease.

An Evaluation of a Project ECHO Mental Health Pilot

Suicide is now the 10th leading cause of death in the US, with over 40,000 people dying by suicide each year, at a cost of about $44B annually.

At CMSC 2017, Aaron Boster, MD, neuroimmunologist for OhioHealth Neurological Clinicians, discussed why he believes there's never been a better time of opportunity for multiple sclerosis patients, and what must be improved in MS diagnosis practice.

Transcranial Magnetic Stimulation (TMS) is getting good results as an adjunctive therapy for patients with major depression who have failed on several antidepressant medications.

The genetic, environmental, and immune factors behind the disease.

Transcranial Magnetic Stimulation (TMS) is an adjunctive therapy for patients with major depression who have failed on several antidepressant medications.

Dr. Melissa Arbuckle explains what neuroscience is and why every practicing psychiatrist should have an understanding and appreciation for this branch of science.